Candel Therapeutics Announces $15 Mln Direct Offering To Fund CAN-2409 Launch Readiness
24/6 19:39
(RTTNews) - Candel Therapeutics, Inc. (CADL), a clinical-stage biopharma company developing immunotherapies for cancer, has entered a registered direct offering with select accredited investors to sell approximately 3.2 million shares of common stock at $4.67 per share....